RU2595861C2 - Новое лечение рассеянного склероза ( рс ) - Google Patents

Новое лечение рассеянного склероза ( рс ) Download PDF

Info

Publication number
RU2595861C2
RU2595861C2 RU2013125470/15A RU2013125470A RU2595861C2 RU 2595861 C2 RU2595861 C2 RU 2595861C2 RU 2013125470/15 A RU2013125470/15 A RU 2013125470/15A RU 2013125470 A RU2013125470 A RU 2013125470A RU 2595861 C2 RU2595861 C2 RU 2595861C2
Authority
RU
Russia
Prior art keywords
flurbiprofen
compound
multiple sclerosis
treatment
present
Prior art date
Application number
RU2013125470/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2013125470A (ru
Inventor
Ирмгард ТЕГЕДЕР
Герд ГАЙССЛИНГЕР
Original Assignee
Фраунхофер-Гезелльшафт Цур Фердерунг Дер Ангевандтен Форшунг Е.Ф.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фраунхофер-Гезелльшафт Цур Фердерунг Дер Ангевандтен Форшунг Е.Ф. filed Critical Фраунхофер-Гезелльшафт Цур Фердерунг Дер Ангевандтен Форшунг Е.Ф.
Publication of RU2013125470A publication Critical patent/RU2013125470A/ru
Application granted granted Critical
Publication of RU2595861C2 publication Critical patent/RU2595861C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2013125470/15A 2010-11-03 2011-11-03 Новое лечение рассеянного склероза ( рс ) RU2595861C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
GB1018519.7 2010-11-03
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Publications (2)

Publication Number Publication Date
RU2013125470A RU2013125470A (ru) 2014-12-10
RU2595861C2 true RU2595861C2 (ru) 2016-08-27

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013125470/15A RU2595861C2 (ru) 2010-11-03 2011-11-03 Новое лечение рассеянного склероза ( рс )

Country Status (10)

Country Link
US (1) US20130309199A1 (https=)
EP (1) EP2635271A1 (https=)
JP (1) JP5903438B2 (https=)
KR (1) KR101877587B1 (https=)
CN (1) CN103209692A (https=)
BR (1) BR112013010883A2 (https=)
CA (1) CA2816911C (https=)
GB (1) GB2485169A (https=)
RU (1) RU2595861C2 (https=)
WO (1) WO2012059541A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN111344287B (zh) 2017-11-14 2023-12-19 默沙东有限责任公司 作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)
CN113880899B (zh) * 2020-10-30 2023-06-23 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2250103C2 (ru) * 1999-02-24 2005-04-20 Пац Арцнаймиттель-Энтвиклунгсгезельшафт мбХ ПРИМЕНЕНИЕ (R)-АРИЛПРОПИОНОВЫХ КИСЛОТ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЛЮДЕЙ И ЖИВОТНЫХ, НА КОТОРЫЕ МОЖНО ОКАЗЫВАТЬ ТЕРАПЕВТИЧЕСКОЕ ВОЗДЕЙСТВИЕ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВАЦИИ NF-κВ
CA2710318A1 (en) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellscaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1587798A4 (en) * 2003-01-14 2007-06-27 Merck & Co Inc GEMINAL DISUBSTITUTED SODIUM DERIVATIVES AS ABETA 42 SUBSTITUTING AGENTS
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
RU2565066C2 (ru) * 2010-04-21 2015-10-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2250103C2 (ru) * 1999-02-24 2005-04-20 Пац Арцнаймиттель-Энтвиклунгсгезельшафт мбХ ПРИМЕНЕНИЕ (R)-АРИЛПРОПИОНОВЫХ КИСЛОТ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЛЮДЕЙ И ЖИВОТНЫХ, НА КОТОРЫЕ МОЖНО ОКАЗЫВАТЬ ТЕРАПЕВТИЧЕСКОЕ ВОЗДЕЙСТВИЕ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВАЦИИ NF-κВ
CA2710318A1 (en) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellscaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FURLAN R et al. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. Journal of Neuroimmunol/ 2004 May ; 15091-2):10-9 [он-лайн] [найдено 18.09.2015] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/15081244). БУРМЕСТЕР Г-Р. и др. Наглядная иммунология М., БИНОМ Лаборатория знаний 2007 с.244 1 колонка 1-й абзац, разделы Г. Клинические проявления, Д. Терапевтические подходы. *

Also Published As

Publication number Publication date
CA2816911A1 (en) 2012-05-10
RU2013125470A (ru) 2014-12-10
BR112013010883A2 (pt) 2016-09-13
GB2485169A (en) 2012-05-09
WO2012059541A1 (en) 2012-05-10
GB201018519D0 (en) 2010-12-15
KR20140017494A (ko) 2014-02-11
KR101877587B1 (ko) 2018-07-11
CN103209692A (zh) 2013-07-17
US20130309199A1 (en) 2013-11-21
JP5903438B2 (ja) 2016-04-13
EP2635271A1 (en) 2013-09-11
CA2816911C (en) 2018-09-25
JP2014505015A (ja) 2014-02-27

Similar Documents

Publication Publication Date Title
RU2595861C2 (ru) Новое лечение рассеянного склероза ( рс )
Barylski et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants
CN102548571B (zh) 用于预防和治疗脑部疾病和疾病状态的组合物和方法
US11690831B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
KR20130036217A (ko) 라퀴니모드를 이용한 루푸스 관절염의 치료
El Miedany et al. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease
JP2011506505A (ja) 痛みを伴う神経障害の治療の際の、医薬並びにその製造方法及び使用
Xu et al. Gastrodin ameliorates postoperative cognitive dysfunction in aged mice by promoting nuclear translocation of Nrf2 through activation of AMPK
Gaudet et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study
US11850252B2 (en) Use of nor-ursodeoxycholic acid for reducing liver fat
Jadidi-Niaragh et al. Therapeutic approach to multiple sclerosis by novel oral drugs
WO2016020944A1 (en) Use in single pill/tablet/capsule of minocycline, fluconazole and atorvastatin in the treatment of multiple sclerosis
US20200360331A1 (en) COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
HK40082338A (en) Application of rxr agonist and thyroid hormone in preparation of medicine for treating autoimmune diseases
Bubnova et al. The hypolipidemic and hepatoprotective efficacies of a essential phospholipids with methionine and atorvastatin in patients with cardiovascular diseases and diabetes mellitus
Alves et al. Is there difference in the lipid profile between diabetic and non diabetic patients at the moment of the statin introduction?